Patient perspectives on the treatment burden of injectable medication for hereditary angioedema
- PMID: 33980327
- DOI: 10.2500/aap.2021.42.210025
Patient perspectives on the treatment burden of injectable medication for hereditary angioedema
Abstract
Hereditary angioedema (HAE) is a rare, chronic disease characterized by debilitating swelling episodes in various parts of the body. Patients experience significant burdens related to the symptoms and management of HAE, which can affect their daily lives and reduce their overall quality of life. Prophylactic treatment options have expanded in the past decade to the benefit of patients; however, these therapies require scheduled injections, which can be painful, burdensome, and time consuming. We conducted an online survey of patients with HAE in the USA to better understand their experiences with available prophylactic medications and the associated treatment burdens. Our survey results suggest that most patients are satisfied with their current therapies but desire novel medications with a simpler route of administration and that, although most patients experience significant treatment-related burdens, they learn to cope with these challenges over time.
Similar articles
-
Physician and patient perspectives on the management of hereditary angioedema: a survey on treatment burden and needs.Allergy Asthma Proc. 2021 May 1;42(3):S17-S25. doi: 10.2500/aap.2021.42.210017. Allergy Asthma Proc. 2021. PMID: 33980329
-
Berotralstat (BCX7353) is a novel oral prophylactic treatment for hereditary angioedema: Review of phase II and III studies.Allergy Asthma Proc. 2021 Jul 14;42(4):274-282. doi: 10.2500/aap.2021.42.210034. Epub 2021 Jun 14. Allergy Asthma Proc. 2021. PMID: 34127176 Review.
-
Caregivers' role in managing hereditary angioedema and perceptions of treatment-related burden.Allergy Asthma Proc. 2021 May 1;42(3):S11-S16. doi: 10.2500/aap.2021.42.210029. Allergy Asthma Proc. 2021. PMID: 33980328
-
Analyzing social media conversations to gain insights into the experiences of patients with hereditary angioedema.Allergy Asthma Proc. 2025 May 1;46(3):218-226. doi: 10.2500/aap.2025.46.250028. Epub 2025 Apr 28. Allergy Asthma Proc. 2025. PMID: 40295108
-
Hereditary angioedema: On-demand treatment of angioedema attacks.Allergy Asthma Proc. 2020 Nov 1;41(Suppl 1):S26-S29. doi: 10.2500/aap.2020.41.200066. Allergy Asthma Proc. 2020. PMID: 33109322 Review.
Cited by
-
Berotralstat for long-term prophylaxis of hereditary angioedema in Japan: Parts 2 and 3 of the randomized APeX-J Phase III trial.World Allergy Organ J. 2024 Mar 2;17(3):100882. doi: 10.1016/j.waojou.2024.100882. eCollection 2024 Mar. World Allergy Organ J. 2024. PMID: 38445295 Free PMC article.
-
Scoping review of measures of treatment burden in patients with multimorbidity: advancements and current gaps.J Clin Epidemiol. 2023 Jul;159:92-105. doi: 10.1016/j.jclinepi.2023.05.013. Epub 2023 May 20. J Clin Epidemiol. 2023. PMID: 37217106 Free PMC article.
-
The allergist and IgE: The realization that allergic diseases are not all IgE mediated.Allergy Asthma Proc. 2021 May 1;42(3):183-186. doi: 10.2500/aap.2021.42.210037. Allergy Asthma Proc. 2021. PMID: 33980330 Free PMC article. No abstract available.
-
Evaluation and management of adverse reactions to the COVID-2019 vaccines.Allergy Asthma Proc. 2022 Jan 1;43(1):1-4. doi: 10.2500/aap.2022.43.210118. Allergy Asthma Proc. 2022. PMID: 34983703 Free PMC article. No abstract available.
-
Asthma biomarkers and COVID-19 continue to dominate current medical issues.Allergy Asthma Proc. 2022 Sep 1;43(5):363-367. doi: 10.2500/aap.2022.43.220062. Allergy Asthma Proc. 2022. PMID: 36065102 Free PMC article. No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous